PubRank

Noriyuki Katsumata

Author PubWeight™ 84.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg 2009 2.02
2 Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004 1.77
3 Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 2010 1.72
4 Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1. J Clin Endocrinol Metab 2004 1.63
5 Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol 2007 1.56
6 Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2011 1.55
7 Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004 1.55
8 Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006 1.25
9 HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 2002 1.25
10 Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2014 1.18
11 A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2009 1.11
12 Mastermind-like domain-containing 1 (MAMLD1 or CXorf6) transactivates the Hes3 promoter, augments testosterone production, and contains the SF1 target sequence. J Biol Chem 2007 1.08
13 Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J Clin Endocrinol Metab 2006 1.06
14 Physician-patient communication and patient satisfaction in Japanese cancer consultations. Soc Sci Med 2002 1.06
15 Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2008 1.05
16 Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 2009 1.03
17 Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 2009 1.02
18 The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J 2003 1.01
19 Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012 1.00
20 A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol 2010 0.98
21 Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 2012 0.96
22 The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 2005 0.96
23 Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 2011 0.95
24 The notorious "drug lag" for oncology drugs in Japan. Invest New Drugs 2011 0.95
25 A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol 2012 0.94
26 An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol 2006 0.93
27 Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist 2009 0.92
28 Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J 2005 0.92
29 [Guidelines for proper use of antineoplastic agents. Gynecologic cancer]. Gan To Kagaku Ryoho 2002 0.91
30 A nationwide attempt to standardize growth hormone assays. Horm Res 2005 0.90
31 Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol 2007 0.90
32 Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. J Cancer Res Clin Oncol 2012 0.90
33 Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res 2012 0.89
34 Determination of specific activities and kinetic constants of biotinidase and lipoamidase in LEW rat and Lactobacillus casei (Shirota). J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.89
35 The interaction between physician and patient communication behaviors in Japanese cancer consultations and the influence of personal and consultation characteristics. Patient Educ Couns 2002 0.89
36 Determination of biotin (vitamin H) by the high-performance affinity chromatography with a trypsin-treated avidin-bound column. J Chromatogr B Analyt Technol Biomed Life Sci 2008 0.88
37 Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. Jpn J Clin Oncol 2003 0.86
38 Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. Oncol Rep 2008 0.86
39 Serous adenocarcinoma of the retroperitoneum, as a type of multifocal müllerian carcinoma. Int J Clin Oncol 2009 0.86
40 Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat 2005 0.85
41 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast 2009 0.85
42 Uniparental disomy of chromosome 8 leading to homozygosity of a CYP11B1 mutation in a patient with congenital adrenal hyperplasia: implication for a rare etiology of an autosomal recessive disorder. Endocr J 2014 0.85
43 Sibling cases of Addison's disease caused by DAX-1 gene mutations. Intern Med 2007 0.85
44 Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J Surg Oncol 2010 0.83
45 [Gynecologic cancer]. Gan To Kagaku Ryoho 2008 0.83
46 Two cases of Allgrove syndrome with mutations in the AAAS gene. Endocr J 2004 0.83
47 Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2011 0.83
48 Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. J Proteome Res 2009 0.83
49 Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol 2010 0.83
50 Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. Eur J Obstet Gynecol Reprod Biol 2011 0.83
51 Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report. Jpn J Clin Oncol 2009 0.83
52 Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 2003 0.83
53 Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 2010 0.83
54 Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. Int J Clin Oncol 2003 0.82
55 A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer 2005 0.82
56 Molecular genetic analysis of MODY candidate genes in Japanese patients with non-obese juvenile onset diabetes mellitus. J Pediatr Endocrinol Metab 2006 0.82
57 Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 2011 0.82
58 A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol 2010 0.82
59 Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. J Cancer Res Clin Oncol 2008 0.81
60 Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer 2003 0.81
61 Progressive osseous heteroplasia caused by a novel nonsense mutation in the GNAS1 gene. J Pediatr Endocrinol Metab 2010 0.81
62 Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practice. Psychooncology 2010 0.81
63 Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol 2008 0.81
64 The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 2006 0.81
65 A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 2003 0.80
66 A novel homozygous mutation of the nicotinamide nucleotide transhydrogenase gene in a Japanese patient with familial glucocorticoid deficiency. Endocr J 2013 0.80
67 Novel C617Y mutation in the 7th transmembrane segment of luteinizing hormone/choriogonadotropin receptor in a Japanese boy with peripheral precocious puberty. Endocr J 2010 0.80
68 Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol 2010 0.80
69 Hypospadias in a male patient with 21-hydroxylase deficiency. Endocr J 2008 0.80
70 U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites. J Hum Genet 2007 0.80
71 Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia. Endocr J 2016 0.80
72 Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat 2008 0.80
73 Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J 2013 0.79
74 Primary yolk sac tumor of the omentum: a case report and literature review. Case Rep Oncol 2012 0.79
75 Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J 2013 0.79
76 Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013 0.79
77 Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol 2009 0.79
78 Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. Jpn J Clin Oncol 2008 0.79
79 NR0B1 Frameshift Mutation in a Boy with Idiopathic Central Precocious Puberty. Sex Dev 2016 0.79
80 Nonclassic steroid 21-hydroxylase deficiency due to a homozygous V281L mutation in CYP21A2 detected by the neonatal mass-screening program in Japan. Endocr J 2007 0.79
81 Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract 2006 0.78
82 Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol 2008 0.78
83 A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemother Pharmacol 2013 0.78
84 Triple A syndrome in Japan. Muscle Nerve 2013 0.78
85 [Treatment of chemotherapy-induced anemia]. Gan To Kagaku Ryoho 2014 0.77
86 [Chemotherapy for recurrent ovarian cancer]. Nihon Rinsho 2012 0.77
87 Satisfying the needs of Japanese cancer patients: a comparative study of detailed and standard informed consent documents. Clin Trials 2014 0.77
88 A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. Invest New Drugs 2014 0.77
89 Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503. Jpn J Clin Oncol 2012 0.77
90 Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J Clin Oncol 2004 0.77
91 Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol 2006 0.77
92 Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. Breast Cancer Res Treat 2006 0.76
93 The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann Surg 2004 0.76
94 X-linked adrenal hypoplasia congenita caused by a novel intronic mutation of the DAX-1 gene. Horm Res 2009 0.76
95 Systematic overview of quality of life studies for breast cancer. Breast Cancer 2002 0.76
96 Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial. Int J Gynecol Cancer 2011 0.75
97 A Case of Allgrove Syndrome with a Novel IVS7 +1 G>A Mutation of The AAAS Gene. Clin Pediatr Endocrinol 2012 0.75
98 Familial glucocorticoid deficiency in five Arab kindreds with homozygous point mutations of the ACTH receptor (MC2R): genotype and phenotype correlations. Horm Res Paediatr 2011 0.75
99 A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. Med Oncol 2010 0.75
100 A case of primary unknown carcinoma with lymphatic spread. Jpn J Clin Oncol 2006 0.75
101 Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial. Jpn J Clin Oncol 2004 0.75
102 Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. Int J Clin Oncol 2005 0.75
103 Questionnaire-based survey on chemotherapy-induced anemia. Int J Clin Oncol 2014 0.75
104 [Acute Hyperuricemia and Kidney Injury after Three Cycles of Dose-Dense Chemotherapy for Retroperitoneal Choriocarcinoma - A Case Report]. Gan To Kagaku Ryoho 2016 0.75
105 The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. Urol Oncol 2010 0.75
106 [Palliative chemotherapy in cancer patients]. Nihon Rinsho 2007 0.75
107 [I. Current Topics of Chemotherapy for Ovarian Cancer]. Gan To Kagaku Ryoho 2017 0.75
108 [Genetic testing for effective Herceptin therapy]. Nihon Rinsho 2002 0.75
109 [Ovarian cancer from the standpoint of medical oncology]. Gan To Kagaku Ryoho 2007 0.75
110 Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol 2006 0.75
111 Two novel HSD3B2 missense mutations with diverse residual enzymatic activities for Δ5-steroids. Clin Endocrinol (Oxf) 2014 0.75
112 Second-line chemotherapy in patients with primary unknown cancer. J Cancer Res Clin Oncol 2011 0.75
113 An immunologically anomalous but considerably bioactive GH produced by a novel GH1 mutation (p.D116E). Eur J Endocrinol 2009 0.75
114 [A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer]. Gan To Kagaku Ryoho 2006 0.75
115 [Ovarian cancer: TC therapy]. Nihon Rinsho 2015 0.75
116 Size-exclusion chromatography of biological samples which contain extremely alkaline proteins. J Biochem Biophys Methods 2003 0.75
117 Novel compound heterozygous AIRE mutations in a Japanese patient with APECED. J Pediatr Endocrinol Metab 2004 0.75
118 Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer. Int J Gynaecol Obstet 2009 0.75
119 Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Res Treat 2008 0.75
120 Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. Int J Clin Oncol 2008 0.75
121 Rhabdomyosarcoma of the Uterus: A Case Report. J Nippon Med Sch 2015 0.75
122 Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors. Oncology 2010 0.75
123 The Third International Congress of the GRS and the IGF Society, November 11-15, 2006, Kobe, Japan. Pediatr Endocrinol Rev 2007 0.75